TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36842439

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (65 Gy in 54 fractions, given twice daily with an interfractional time interval of at least 6 h)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard fractionation (60 Gy in 27 fractions, given once a day)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Hyperfractionation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard fractionation
Number of subjects: 144
Study: 36842446

Group type: EXPERIMENTAL
Intervention: Deutivacaftor 150 mg once daily
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Deutivacaftor 250 mg once daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Elexacaftor-tezacaftor-ivacaftor (control group)
Number of subjects: 47
Study: 36842451

Group type: EXPERIMENTAL
Intervention: Total fructose-containing sugars
Number of subjects: 10357

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (SSBs) at high doses (≥20%E or 100 g/d)
Number of subjects: 10357

Group type: EXPERIMENTAL
Intervention: Removal of sugars
Number of subjects: 10357

Group type: EXPERIMENTAL
Intervention: Fruits at lower doses (≤10%E or 50 g/d)
Number of subjects: 10357

Group type: EXPERIMENTAL
Intervention: Other food sources of sugars
Number of subjects: 10357
Study: 36842486

Group type: EXPERIMENTAL
Intervention: Telemonitoring-based HF disease management (n=159)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Telephone-based HF disease management (n=53)
Number of subjects: 212
Study: 36842489

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 36842666

Group type: EXPERIMENTAL
Intervention: Deep learning model combining CT and RD images
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Adjusted deep learning model using CT and RD weights
Number of subjects: 314
Study: 36842675

Group type: EXPERIMENTAL
Intervention: High IFABP group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low IFABP group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IFABP
Number of subjects: 50
Study: 36842754

Group type: EXPERIMENTAL
Intervention: Rapeseed protein
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Flaxseed protein
Number of subjects: 19
Study: 36842841

Group type: EXPERIMENTAL
Intervention: Plasma amyloid beta ratio (AβR) increase from preoperative to postoperative Day 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Change in plasma AβR
Number of subjects: 100
Study: 36842849

Group type: EXPERIMENTAL
Intervention: relmacabtagene autoleucel (relma-cel) infusion after lymphodepletion chemotherapy
Number of subjects: 68
Study: 36842886

Group type: EXPERIMENTAL
Intervention: AKS-452 (90 µg single dose)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AKS-452 (two 45 µg doses 28 days apart)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AKS-452 (both cohorts)
Number of subjects: 52
Study: 36842956

Group type: EXPERIMENTAL
Intervention: Carbohydrate metrics
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dietary fiber RDA
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Overall carbohydrate quality measures
Number of subjects: 104
Study: 36842964

Group type: EXPERIMENTAL
Intervention: High-dose tandospirone (60 mg/d)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Low-dose tandospirone (30 mg/d)
Number of subjects: 274
Study: 36843239

Group type: EXPERIMENTAL
Intervention: CPAP therapy for 3 months
Number of subjects: 220
Study: 36843256

Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MLC901
Number of subjects: 0
Study: 36843368

Group type: EXPERIMENTAL
Intervention: Bilateral superficial trigeminal nerve blocks (0.5% ropivacaine with epi 1:200,000)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo/sham (0.9% normal saline)
Number of subjects: 46
Study: 36843446

Group type: EXPERIMENTAL
Intervention: Behavioral intervention based on social cognitive theory (SCT) delivered through the Internet using e-learning approaches
Number of subjects: 0
Study: 36843567

Group type: EXPERIMENTAL
Intervention: Flipped classroom model
Number of subjects: 66
Study: 36843975

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation 1000 IU
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation 200 IU
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 101
Study: 36844198

Group type: EXPERIMENTAL
Intervention: MOTS-c
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Romo1
Number of subjects: 142
Study: 36844736

Group type: EXPERIMENTAL
Intervention: Pyrotinib plus trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pertuzumab plus trastuzumab
Number of subjects: 0
Study: 36844740

Group type: EXPERIMENTAL
Intervention: Wrist-worn device combining PPG and ECG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intermittent 30 s Lead I ECG
Number of subjects: 30
Study: 36845050

Group type: EXPERIMENTAL
Intervention: Oral ketone ester (395 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 36845426

Group type: EXPERIMENTAL
Intervention: Percutaneous HFAC at 30 kHz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 36845633

Group type: EXPERIMENTAL
Intervention: Single fraction of preoperative radiotherapy (6 to 14 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care treatment (maximal safe resection and postoperative chemoradiotherapy with 60 Gy/30 fr and concurrent/adjuvant temozolomide)
Number of subjects: 0
Study: 36845654

Group type: EXPERIMENTAL
Intervention: High-frequency WB-EMS strength training (HFG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-frequency WB-EMS aerobic training (LFG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inactive control group (CG)
Number of subjects: 24
Study: 36845705

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks) and escalating doses of IL-2 (6,000 or 60,000 or 600,000 IU/kg IV bolus every 8 hours up to 14 doses per cycle)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-dose IL-2 therapy in combination with pembrolizumab
Number of subjects: 10
Study: 36846138

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin
Number of subjects: 344

Group type: COMPARATOR
Intervention: Low-dose atorvastatin
Number of subjects: 344
Study: 36846414

Group type: EXPERIMENTAL
Intervention: HEAR-QL questionnaire
Number of subjects: 1173
Study: 36846600

Group type: EXPERIMENTAL
Intervention: Lungs from DCD donors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lungs from DBD donors
Number of subjects: 0
Study: 36846961

Group type: EXPERIMENTAL
Intervention: Preserved CFR and low IMR (group 1)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Preserved CFR and elevated IMR (group 2)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Depressed CFR and low IMR (group 3)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Depressed CFR and elevated IMR (group 4)
Number of subjects: 375
Study: 36846982

Group type: EXPERIMENTAL
Intervention: Predictive model based on sex, previous history of intracranial aneurysm/aSAH, and older age score
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Risk of new intracranial aneurysms
Number of subjects: 499
Study: 36847256

Group type: EXPERIMENTAL
Intervention: Detectable ctDNA before surgery
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ctDNA positivity at postsurgery time points
Number of subjects: 47

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 47
Study: 36847281

Group type: EXPERIMENTAL
Intervention: Open Latarjet procedure on the dominant side
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Open Latarjet procedure on the nondominant side
Number of subjects: 133

Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 133
Study: 36847333

Group type: EXPERIMENTAL
Intervention: Daily blueberry consumption for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36847750

Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release (viloxazine ER; 100 to 600 mg/day)
Number of subjects: 1354

Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release (viloxazine ER)
Number of subjects: 1354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1354
Study: 36847909

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 22

Group type: COMPARATOR
Intervention: Diode laser
Number of subjects: 22
Study: 36847952

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist (GLP-1RA)
Number of subjects: 7392

Group type: EXPERIMENTAL
Intervention: GLP-1RA
Number of subjects: 7392

Group type: COMPARATOR
Intervention: Non-users of GLP-1RA
Number of subjects: 7392

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 7392
Study: 36847979

Group type: EXPERIMENTAL
Intervention: Ultra-low-frequency pressure reactivity index (UL-PRx)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mean UL-PRx and % time with ICP > 20 mmHg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Secondary decompressive craniectomy
Number of subjects: 47
Study: 36847995

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention conducted by pharmacy students, consisting of an initial call and five follow-up calls
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group (no MI intervention)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 720
Study: 36848061

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT), Mindfulness-based stress reduction (MBSR), Behavior therapy (BT)
Number of subjects: 0
Study: 36848113

Group type: EXPERIMENTAL
Intervention: Intranasal mometasone (INC group) - 1 application per nostril, once per day for 12 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: 3-mL sodium chloride (NaCl), 0.9%, solution in a nasal nebulizer once a day for 12 weeks (control group)
Number of subjects: 66
Study: 36848119

Group type: EXPERIMENTAL
Intervention: SPARC intervention (practice facilitation, electronic health record decision support, performance feedback)
Number of subjects: 333596

Group type: EXPERIMENTAL
Intervention: SPARC intervention
Number of subjects: 333596
Study: 36848129

Group type: EXPERIMENTAL
Intervention: Opt-out care
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Opt-in care
Number of subjects: 1000
Study: 36848207

Group type: EXPERIMENTAL
Intervention: Mobile instant messaging (IM) apps for alcohol reduction intervention
Number of subjects: 20
Study: 36848226

Group type: EXPERIMENTAL
Intervention: Lifestyle behavior changes during the COVID-19 pandemic
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Body image perception, change in stress level, and gender identity
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Mean BMI
Number of subjects: 1609
Study: 36848258

Group type: EXPERIMENTAL
Intervention: Second glaucoma drainage device (SGDD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Transscleral cyclophotocoagulation (CPC)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SGDD
Number of subjects: 42

Group type: COMPARATOR
Intervention: CPC
Number of subjects: 42
Study: 36848311

Group type: EXPERIMENTAL
Intervention: Corticosteroids (administered to 18 patients, 19% of TMP-SMZ group)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No corticosteroids (untreated patients)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: TMP-SMZ treatment
Number of subjects: 105
Study: 36848344

Group type: EXPERIMENTAL
Intervention: Colonization of intervertebral discs by Cutibacterium acnes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiomic analyses of LLIVD colonized and non-colonized
Number of subjects: 0
Study: 36848432

Group type: EXPERIMENTAL
Intervention: Direct transport to a thrombectomy-capable center during nighttime
Number of subjects: 949

Group type: COMPARATOR
Intervention: Transfer to the nearest local stroke center during nighttime
Number of subjects: 949
Study: 36848607

Group type: EXPERIMENTAL
Intervention: Plasma GAGome progression score
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Urine GAGome progression score
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined GAGome progression score
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasma GAGome progression score (external validation)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall sensitivity and specificity
Number of subjects: 50
Study: 36848614

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36848635

Group type: EXPERIMENTAL
Intervention: Weekly dose-adjusted prophylaxis (starting dose, 50 IU/kg) in B-LONG study
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Individualized interval-adjusted prophylaxis (initially, 100 IU/kg every 10 days) in B-LONG study
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: On-demand dosing in B-LONG study
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 50 to 60 IU/kg every 7 days in Kids B-LONG study
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Weekly prophylaxis (20-100 IU/kg every 7 days) in B-YOND study
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Individualized prophylaxis (100 IU/kg every 8-16 days) in B-YOND study
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Modified prophylaxis in B-YOND study
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: On-demand dosing in B-YOND study
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Overall rFIXFc prophylaxis
Number of subjects: 153
Study: 36848639

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan 1080 mg subcutaneously twice weekly for 26 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Supportive care only (control)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 53
Study: 36848714

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CPT with written accounts (CPT+A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Written accounts (WA)
Number of subjects: 150
Study: 36848727

Group type: EXPERIMENTAL
Intervention: Question prompt list and video intervention
Number of subjects: 189

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 189
Study: 36848897

Group type: EXPERIMENTAL
Intervention: Zinc supplementation along with oral rehydration solution (ORS)
Number of subjects: 1399

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 1399
Study: 36848918

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study: 36848919

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 775

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 775
Study: 36848922

Group type: EXPERIMENTAL
Intervention: Metabolic and bariatric surgery (MBS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intensive non-surgical treatment
Number of subjects: 50
Study: 36849009

Group type: EXPERIMENTAL
Intervention: mogroside V and stevia RebM
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: stevia RebA and thaumatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: stevia RebA-thaumatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: sucralose-ace-K
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: sucralose-acesulfame K
Number of subjects: 60

Group type: COMPARATOR
Intervention: sucrose
Number of subjects: 60
Study: 36849097

Group type: EXPERIMENTAL
Intervention: MCDBT-1
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: MCDBT-2
Number of subjects: 1693
Study: 36849106

Group type: EXPERIMENTAL
Intervention: Infinity brush
Number of subjects: 51

Group type: COMPARATOR
Intervention: RX Cytology Brush
Number of subjects: 51
Study: 36849161

Group type: EXPERIMENTAL
Intervention: Micro-particle curcumin (90 mg/day)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study: 36849193

Group type: EXPERIMENTAL
Intervention: Adherence Monitoring Package (AMoPac)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GPs' acceptance of AMoPac
Number of subjects: 7

Group type: COMPARATOR
Intervention: Integrated transmission of adherence reports to GPs
Number of subjects: 7
Study: 36849205

Group type: EXPERIMENTAL
Intervention: Adjunctive triamcinolone acetonide (TA)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 280
Study: 36849212

Group type: EXPERIMENTAL
Intervention: GIP infusion (16 pmol/kg/min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Semaglutide injections (0.5 mg once-weekly)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (subcutaneous)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous placebo (subcutaneous)
Number of subjects: 60
Study: 36849448

Group type: EXPERIMENTAL
Intervention: University of Pennsylvania Smell Identification Test (UPSIT)
Number of subjects: 9396

Group type: COMPARATOR
Intervention: Self-reported hyposmia
Number of subjects: 9396
Study: 36849494

Group type: EXPERIMENTAL
Intervention: First-line osimertinib
Number of subjects: 0
Study: 36849516

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 78
Study: 36849732

Group type: EXPERIMENTAL
Intervention: Erythritol ingestion in healthy volunteers (n=8)
Number of subjects: 4139

Group type: COMPARATOR
Intervention: Erythritol (circulating levels)
Number of subjects: 4139
Study: 36849753

Group type: EXPERIMENTAL
Intervention: Laparoscopic major hepatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open major hepatectomy
Number of subjects: 0
Study: 36849797

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (onabotA) injections
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pre onabotA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active onabotA
Number of subjects: 10
Study: 36849838

Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine (two-dose vaccination)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Healthy controls (two-dose vaccination)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Number of subjects: 93
Study: 36849841

Group type: EXPERIMENTAL
Intervention: Integrated intervention (INT)
Number of subjects: 631
Study: 36849955

Group type: EXPERIMENTAL
Intervention: Chidamide + Cladribine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single drug control (either Chidamide or Cladribine)
Number of subjects: 0
Study: 36849969

Group type: EXPERIMENTAL
Intervention: Masitinib 4.5 mg/kg/day
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Masitinib 6.0 mg/kg/day (titrated)
Number of subjects: 358
Study: 36849984

Group type: EXPERIMENTAL
Intervention: Near-death experience (NDE) assessment using the Greyson NDE scale (cut-off score ≥ 7/32)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Quality of life assessment using the EuroQol five-dimensional questionnaire
Number of subjects: 126
Study: 36849990

Group type: EXPERIMENTAL
Intervention: Real bihemispheric tDCS (20 min, 2 mA, during task practice twice daily for 20 sessions in two weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham bihemispheric tDCS
Number of subjects: 27
Study: 36849996

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (no HCQ)
Number of subjects: 68
Study: 36850012

Group type: EXPERIMENTAL
Intervention: Sling immobilization for the first three postoperative weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: No sling immobilization
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sling immobilization
Number of subjects: 68
Study: 36851177

Group type: EXPERIMENTAL
Intervention: WIV04 vaccine (5μg of inactivated SARS-CoV-2 virion adsorbed into aluminum hydroxide in a 0.5 mL aqueous suspension)
Number of subjects: 9309

Group type: EXPERIMENTAL
Intervention: HB02 vaccine (4μg of inactivated SARS-CoV-2 virion adsorbed into aluminum hydroxide in a 0.5 mL aqueous suspension)
Number of subjects: 9309

Group type: COMPARATOR
Intervention: Alum-only group (control)
Number of subjects: 9309

Group type: EXPERIMENTAL
Intervention: All groups (WIV04, HB02, alum-only)
Number of subjects: 9309
Study: 36851196

Group type: EXPERIMENTAL
Intervention: CV0501 mRNA-based Omicron COVID-19 vaccination (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalent vaccine formulations (specific dosage and duration not mentioned)
Number of subjects: 0
Study: 36851204

Group type: EXPERIMENTAL
Intervention: 20 µg + 5 µg vaccine formulation
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 20 µg + 20 µg vaccine formulation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 36851617

Group type: EXPERIMENTAL
Intervention: HIV-1C tropism analysis using genotypic tools
Number of subjects: 5602
Study: 36851662

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine with previous infection
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Infection
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 103
Study: 36852100

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention group (10 sessions over approximately 5 weeks)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Guided relaxation intervention group (video sessions ranging from 2 to 20 min each viewed daily over 5 weeks)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual care group (standard clinical care for sickle cell disease)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention group
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Guided relaxation intervention group
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 366